Skip to main content

A team of AIDS researchers in Hong Kong says its new research, tested on mice, indicates a functional cure for HIV, the virus that causes AIDS, eventually leading to a new antibody that could be used for both prevention and treatment.

The findings, published in the Journal of Clinical Investigation, come as China faces a growing epidemic among high-risk groups, such as sex workers and men who have sex with men.

The U.N.-supported AIDS Data Hub says about 850,000 people in China are infected with HIV, which disables the immune system and makes people far more vulnerable to infections and disease.

Story continues below advertisement

A team led by Professor Chen Zhiwei at Hong Kong University’s AIDS Institute says its discovery, tested on mice, shows the new antibody can help control the virus and eliminate infected cells.

The antibody would be able to treat all varieties of HIV – a first, Chen said - as there is no one vaccine to treat the many different types of HIV viruses.

A research team at Hong Kong University's AIDS Institute says it may have found a "functional cure" to HIV, the virus that causes AIDS, in a major breakthrough that could see a new antibody be used for both prevention and treatment. Reuters

“For our newly discovered bispecific antibody, it works for all of them, so that’s the major difference,” Chen told Reuters.

Chen and his team say they aim to bring the antibody into clinical trials within a timeframe of three to five years.

Chen said a “functional cure” meant the virus level would be so low as to be undetectable in the body, as long as patients kept taking injections of the antibody, perhaps on a quarterly basis, or less frequently.

Those infected with HIV can keep the virus under control with antiretroviral drugs that stop it from infecting new cells.

However, treatments must be taken daily and do not eliminate the infected cells from the body. So the virus can still exist, and symptoms return, if patients stop taking medication properly.

Story continues below advertisement

The new antibody would have a significantly longer half-life than current treatments, and could, for example, be administered on a quarterly basis, Chen said, making it easier than the daily treatment most HIV-infected patients face.

Promising results did not mean the treatment would be readily available soon, said Andrew Chidgey, chief executive of the charity group AIDS Concern in Hong Kong.

“Governments are being very slow to implement programmes here,” he added. “So just because a treatment becomes available, doesn’t mean that people will get it, or that it will have an impact.”

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter